MedPath

Shanxi C&y Pharmaceutical Group Co.,Ltd

Ownership
-
Established
2005-03-23
Employees
479
Market Cap
-
Website
www.cy-pharm.com
Introduction

The company is a listed pharmaceutical group enterprise integrating R&D, production and marketing. The company's predecessor, Shanxi Qianyuan Pharmaceutical Co., Ltd., was established on March 23, 2005. Since then, it has grown from a small pharmaceutical company with only 100 employees and 2 main products. It has provided products and services across 34 provincial administrative regions across the country, and has gradually expanded its business to the international market and precision medicine. The company changed its name to Shanxi Qianyuan Pharmaceutical Co., Ltd. in June 2010 and was successfully listed on the Shenzhen Stock Exchange GEM on August 19, 2011. In September 2014, the company changed its name to Shanxi Qianyuan Pharmaceutical Group Co., Ltd. It is mainly engaged in R&D, production and sales of pharmaceuticals and health foods, medical and health services and commercial business such as medical diagnosis, gene preservation, and pregnancy environment testing. The company's pharmaceutical product categories include anti-infectives, anti-allergic drugs, respiratory drugs, urinary system drugs, nephropathy drugs, pediatric drugs, cardiovascular drugs, antidepressants, pharmaceutical raw materials and intermediates. The main varieties are: fosfomycin, tamsulosin hydrochloride sustained-release capsules, ebastine tablets, cinacarcetin hydrochloride tablets, vitamin AD drops, ambroxol hydrochloride dispersible tablets, montmorillonite powder, fluoxetine hydrochloride capsules, apixaban tablets, rivacaban tablets, glucosamine hydrochloride (glucosamine hydrochloride) APIs), etc.; The company's health food mainly includes varieties such as Baoling Gengbao oral liquid, etc., and the company's medical and health services include Medical tests, gene preservation services, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

181

NMPA:181

Drug Approvals

Fluoxetine Hydrochloride Capsules

Product Name
盐酸氟西汀胶囊
Approval Number
国药准字H20073985
Approval Date
Sep 1, 2022
NMPA

Paracetamol Tablets

Product Name
对乙酰氨基酚片
Approval Number
国药准字H14022378
Approval Date
Apr 18, 2022
NMPA

Metronidazole Tablets

Product Name
甲硝唑片
Approval Number
国药准字H14020297
Approval Date
Apr 18, 2022
NMPA

Compound Paracetamol Tablets

Product Name
复方对乙酰氨基酚片
Approval Number
国药准字H14022541
Approval Date
Apr 18, 2022
NMPA

Vitamin U,Belladonna and Aluminium Capsules

Product Name
维U颠茄铝胶囊
Approval Number
国药准字H14022987
Approval Date
Apr 18, 2022
NMPA

Vitamin B1 Tablets

Product Name
维生素B1片
Approval Number
国药准字H14023246
Approval Date
Apr 18, 2022
NMPA

Carbamazepine Tablets

Product Name
卡马西平片
Approval Number
国药准字H14020630
Approval Date
Apr 18, 2022
NMPA

Norfloxacin Capsules

Product Name
诺氟沙星胶囊
Approval Number
国药准字H14022260
Approval Date
Apr 18, 2022
NMPA

Chlorphenamine Maleate Tablets

Product Name
马来酸氯苯那敏片
Approval Number
国药准字H14021924
Approval Date
Apr 18, 2022
NMPA

Ibuprofen Tablets

Product Name
布洛芬片
Approval Number
国药准字H14023250
Approval Date
Apr 18, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 19
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.